Company news

Vir Biotechnology, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19

March 25, 2021

Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19

March 9, 2021

Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19

March 2, 2021

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

February 24, 2021

GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses

February 16, 2021

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

February 10, 2021

Vir Biotechnology Announces New Data Highlighting the Importance of Targeting Conserved Regions of the SARS-CoV-2 Spike Protein in the Development of Therapeutics

January 31, 2021

Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

January 26, 2021

Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

January 26, 2021

Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen

January 25, 2021

Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19

January 11, 2021

Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus

January 11, 2021

Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform

January 5, 2021

Vir Biotechnology to Present at 39th Annual J.P. Morgan Healthcare Conference

January 4, 2021

Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19

December 16, 2020

Vir Biotechnology Appoints Jeffrey Hatfield to its Board of Directors

December 9, 2020

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2020 Financial Results

November 9, 2020

Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K

November 5, 2020

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020

October 26, 2020

Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020

October 20, 2020

Vir and Alnylam to Webcast Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus Mini-Conference

October 12, 2020

Nature Publishes New Research from Vir Biotechnology Demonstrating the Capacity of Enhanced Monoclonal Antibodies to Induce Protective Adaptive Immunity to Viral Infection

October 8, 2020

Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19

October 5, 2020

Vir Biotechnology Appoints Janet Napolitano to its Board of Directors

August 31, 2020

Vir Biotechnology and GSK Start Phase 2/3 Study of COVID-19 Antibody Treatment

August 30, 2020

Vir Biotechnology Presents Data on VIR-2218 from Clinical Studies for the Treatment of Hepatitis B at the EASL Digital International Liver Congress™

August 19, 2020

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results

August 10, 2020

Vir Biotechnology Appoints Elliott Sigal, M.D., Ph.D. to Board of Directors

July 9, 2020

Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment

May 28, 2020

Vir Biotechnology Initiates Phase 1 Clinical Trial of VIR-3434 for Chronic Hepatitis B Virus Infection

May 26, 2020

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results

May 11, 2020

Vir Biotechnology Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

May 7, 2020

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2020 Financial Results on May 12, 2020

April 27, 2020

VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial

April 14, 2020

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

March 25, 2020

Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19

March 24, 2020

Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19

March 11, 2020

Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses

March 10, 2020

Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19

February 24, 2020

Vir Biotechnology Identifies Two Antibodies That Bind to the Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2

February 11, 2020

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2019 Financial Results

November 18, 2019

Vir Biotechnology Announces Pricing of Initial Public Offering

October 9, 2019

← Newer news releases

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 30 decks. Every deck is listed under its year.